Are Peptides Legal? The 2026 FDA Review Explained

If you have been reading about peptides lately, you have probably encountered two claims that cannot both be right. One says peptides were just approved and are about to become widely available. The other says most of them are unapproved substances you should not be injecting.

Both are describing something real, because “peptide” is not one category. Some peptides are FDA-approved prescription medications you may already know by name. Others are not FDA-approved, and whether a particular substance can lawfully be compounded or dispensed depends on the substance, the circumstances, and applicable federal and state requirements. In July 2026 an FDA advisory committee recommended that six of the seven substances it reviewed be added to the 503A Bulks List. That list is part of the federal framework governing when certain bulk drug substances may be used in pharmacy compounding. The recommendations were nonbinding and did not themselves change the regulatory status of anything.

This guide explains where each group stands, what the July vote did and did not do, and how to tell what you are being offered. If you are still working out what the word covers in the first place, our plain-language guide to what peptides are is the better starting point.

“Peptide” describes a shape, not a category of treatment

A peptide is simply a short chain of amino acids. That is a description of molecular structure, not of purpose, safety, or approval status.

This is why the word gets confusing. Semaglutide, the active ingredient in Ozempic and Wegovy, is a peptide. So is tirzepatide. So is insulin. These are FDA-approved medications for specific uses.

The same word also appears on vials sold online labeled “for research use only, not for human consumption.” Those are also peptides. The molecular category tells you nothing about which one you are holding.

Marketing takes advantage of this. A clinic can describe itself as offering “peptide therapy” and be referring to an FDA-approved drug, a compounded preparation, or an unapproved substance. The useful question is never whether something is a peptide. It is what specific substance it is, and what its regulatory status is.

Where things actually stand

There are three groups worth separating, and the differences between them matter more than anything else in this article.

Table: The three regulatory groups

Group	Examples	What it means in practice
FDA-approved medications	Insulin, semaglutide, tirzepatide, liraglutide	Reviewed by the FDA for safety and effectiveness for specific uses. A prescription is required. Federal law limits when pharmacies and outsourcing facilities may compound products that are essentially copies of commercially available FDA-approved drugs.
Compounded preparations	Varies, and changes over time	Compounded drugs are not FDA-approved. Compounding and dispensing are subject to specific federal and state requirements.
Unapproved or investigational substances	BPC-157, TB-500, KPV, MOTS-c, Epitalon, Semax, and others	These are not FDA-approved drugs. Whether a particular substance may be used in pharmacy compounding depends on current federal requirements and FDA policy, which can change. This is the group the July 2026 meeting was about.

 

One caution about the table itself: these are useful groupings for understanding what you are looking at, not three tidy legal boxes. The rules are considerably more detailed than a single row can capture, they distinguish between different types of facility, and they change. A substance can also sit in more than one place at once, since an approved drug and an unapproved copy of it are not the same product.

What happened in July 2026

On July 23 and 24, 2026, the FDA’s Pharmacy Compounding Advisory Committee reviewed seven substances for possible inclusion on the 503A Bulks List.

The committee recommended six of the seven for inclusion and did not recommend emideltide.

These were recommendations to the FDA, not decisions by it, and none of the votes made any of these substances an FDA-approved drug.

Table: What the committee reviewed

Substance	Use evaluated in the FDA’s review	Committee recommendation
BPC-157	Ulcerative colitis	Recommended for inclusion
KPV	See FDA review materials	Recommended for inclusion
TB-500	Wound healing	Recommended for inclusion
MOTS-c	Obesity and osteoporosis	Recommended for inclusion
Semax	Cerebral ischemia, migraine, trigeminal neuralgia	Recommended for inclusion
Epitalon	Insomnia	Recommended for inclusion
Emideltide	See FDA review materials	Not recommended

 

The middle column describes the proposed uses the FDA’s review examined. It is not a list of uses that have been established, and it is not how these substances are marketed online, which is usually broader. A recommendation about compounding eligibility is not a finding that a substance works for anything.

You can read the committee’s materials on FDA’s meeting page for the July 23 and 24, 2026 session.

What the vote does, and what it does not do

This is the part most coverage gets wrong, and it is worth being precise about.

An advisory committee vote is a recommendation, not a decision. The committee advises the FDA. The agency then reviews the full record and makes its own determination, and it is not required to follow the recommendation.

The advisory vote itself did not authorize compounding of these substances. It also did not change their regulatory status.

Inclusion on the 503A Bulks List would not make a substance an FDA-approved drug. The two are different things. A compounded drug is not FDA-approved, and a prescription from a licensed healthcare provider would still be involved.

Nothing about the vote changes how consumer peptide websites should be viewed. That was true before July and it remains true now.

You may encounter marketing that blurs these distinctions, including language suggesting approval is imminent or already effectively done. Treat confident predictions about a pending regulatory decision as what they are.

The “research use only” label

If you search for any of these substances, you will find websites selling them. Most carry some version of a label saying the product is for laboratory research and not for human consumption.

Labels like these do not mean the product is an FDA-approved medication for patient use. They should not be read as evidence that the product is safe, sterile, accurately labeled, or appropriate to use in people.

They are also not a guarantee of anything about the seller. The FDA has taken enforcement action against sellers whose products carried exactly those labels, concluding from the surrounding marketing that the products were intended as drugs for human use regardless of the disclaimer. The label is not a regulatory exemption.

What matters more than the label is what the product is and where it came from. Products obtained outside regulated medication channels may not provide the same assurances about identity, strength, purity, sterility, or manufacturing quality as FDA-approved drugs and appropriately compounded medications. They may also be obtained without the medication review, clinical evaluation, pharmacy oversight, and other safeguards that normally accompany prescription treatment.

If you find yourself reasoning around a label that says a product is not for human consumption, that is worth noticing.

Questions worth asking anyone selling you peptides

These questions can help you understand what is being offered and identify potential warning signs. They apply to us as much as anyone.

• What exactly is the substance, by name? “A peptide blend” is not an answer. You should be able to learn precisely what you would be taking.
• What is its regulatory status? An FDA-approved drug, a compounded preparation prepared under applicable requirements, or neither. If the seller cannot clearly explain the product’s regulatory status, consider that a warning sign.
• Is a licensed healthcare provider evaluating whether this is appropriate for me? Not a questionnaire that approves everyone. An actual clinical assessment.
• Where is it prepared and dispensed? Ask for the name of the pharmacy or facility involved and whether it operates under applicable federal and state requirements.
• Will anyone review this against my other medications and conditions?
• What happens if I have a reaction? There should be a clinician to contact.

Where MyPhysician360 stands

Our position is straightforward, and we would rather state it plainly than be vague about it.

We work only with peptide medications that are FDA-approved, or with compounded preparations that meet applicable federal and state requirements. We do not offer unapproved or investigational substances, and we do not source from research chemical suppliers or grey market sellers. That means our current peptide offering is deliberately narrow.

If you are considering a peptide because of a symptom or health concern, a licensed healthcare provider can evaluate the concern itself rather than starting with a particular product. Men’s energy and hormonal health, thyroid and hormonal conditions, and Medical Weight Support are the usual starting points.

Common questions

Are peptides legal?

There is no single legal status for “peptides.” Some peptide medications are FDA-approved prescription drugs. Other peptide substances are not FDA-approved. Whether a particular substance can lawfully be compounded or dispensed depends on the substance, the circumstances, and applicable federal and state requirements.

Is BPC-157 legal now?

BPC-157 is not an FDA-approved drug. In July 2026, an FDA advisory committee recommended adding BPC-157 to the 503A Bulks List. The recommendation itself did not change BPC-157’s regulatory status or make it an FDA-approved drug. Because FDA policy and applicable requirements can change, check current FDA information for the latest status.

If a substance is added to the 503A Bulks List, does that mean the FDA approved it?

No. Inclusion on the 503A Bulks List and FDA approval of a drug are different things. Compounded drugs are not FDA-approved.

Can a doctor prescribe peptides?

A licensed healthcare provider can prescribe FDA-approved peptide medications when medically appropriate. Compounded medications are different: whether a particular substance may be compounded depends on federal and state requirements and the circumstances of the prescription. A compounded drug is not the same as an FDA-approved drug.

Are semaglutide and tirzepatide peptides?

Yes. Both are peptide medications and both are FDA-approved for specific uses. They are a useful reminder that “peptide” by itself says nothing about whether something is well established. Medical Weight Support covers how those are used.

What about NAD+ and glutathione?

These are often grouped with peptides in marketing, though they are different kinds of molecules. The same principle applies: ask what the substance is, what its status is, and who is evaluating whether it is appropriate for you.

I have already been ordering peptides online. What should I do?

Tell a licensed healthcare provider what you have been taking. Not to be lectured, but because it belongs in your medical record alongside your other medications, and because anything you inject is relevant to your care.

What to do from here

If you are considering peptides, the most useful step is to find out exactly what substance is being offered and what its actual regulatory status is. That single question resolves most of the confusion in this space.

If you are already taking something obtained online, mention it at your next visit. A provider needs to know what you are taking to advise you well.

And if a symptom or health concern is what brought you here, it is worth having that evaluated directly. A licensed healthcare provider can look at what may be contributing and explain which options are appropriate for you. You can review what a visit costs before you start.

We update this article when the FDA acts. For the broader explanation of what the word covers, see what are peptides.

Sources

• U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee meeting, July 23 and 24, 2026. Meeting page and briefing materials.
• U.S. Food and Drug Administration. Bulk drug substances nominated for use in compounding under section 503A.
• U.S. Food and Drug Administration. Warning letter concerning peptide products labeled for research use only.
• FDA’s Advisory Committee Votes on Peptides: What It Does and Doesn’t Do. Legal analysis, July 29, 2026.

Medical disclaimer. This article is for general educational purposes and does not constitute medical advice, and it is not an endorsement of any peptide for any use. Regulatory information described here reflects the situation as of the review date above and may change. A substance should not be treated as an FDA-approved medication simply because it has been discussed or reviewed by an FDA advisory committee. Any treatment decision requires evaluation by a licensed healthcare provider. MyPhysician360 services are available in most states; services are not currently available in Mississippi or Alaska.